Fig. 6

SNX5422 suppresses tumor growth in PRCC xenografts (A) The flanks of NSG mice were implanted with UOK345 or UOK342 cells to establish subcutaneous xenografts. Approximately four weeks following injection, mice bearing tumors were randomized and divided into 2 groups (UOK345: n = 8, each group; UOK342: n = 10, each group) and treated with either SNX5422 (30 mg/kg week, 3 times a week, for 5 weeks) or vehicle control. B The graph depicts changes in tumor volume (mm3) over 5 weeks of treatment. Data represented as mean ± SEM. C Photograph showing excised tumor xenografts in control and treated mice (n = 3, each group) after 5 weeks of treatment. D Kaplan–Meier survival curve of mice treated with SNX5422 or control vehicle in which a log rank (Mantel-Cox) test was used for significance; p < 0.05 was considered significant. The experimental end point (maximum tumor volume) was considered for KM survival plot. E Ki-67 (proliferation) levels were assessed by immunohistofluorescence in tumors of SNX5422 or control-treated mice. Scale bars: 20 μm. F Expression of MET and AKT in UOK345 and UOK342 tumor xenogratfs. Excised tumor xenografts of SNX5422 treated (T1, T2 and T3; n = 3) and control (C1, C2, C3; n = 3) mice were lysed and subjected to western blotting (G) Relative mRNA expression of CDC20, FOXM1, BUB1B, BIRC5 and PLK1 genes in UOK345 and UOK342 tumor xenogratfs. RNA was isolated from excised tumor xenografts of SNX5422 treated and control mice for qRealTime-PCR. Data are presented as mean ± SEM (n = 3 mice, each group); *p < 0.05 is considered significant and was calculated by two tailed Student’s t test or other tests